Nautilus Biotechnology is trading 12.86% up at $2.33, with no company-specific announcement explaining the move.
- Its latest release scheduled third-quarter results for October 27.
- Merck KGaA agreed to acquire Silence Therapeutics for approximately $1.3 billion; reporting does not directly link the deal to Nautilus’s rise.
- Sector signals were mixed: supplied trend coverage cited biotech strength, while other reporting said the XBI had recently fallen.